Clinical risk factors of licorice-induced pseudohyperaldosteronism: a 2026-updated narrative review
- 1Center for Kampo Medicine, Keio University School of Medicine
- 2Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University
Abstract
Pseudohyperaldosteronism induced by the root of Glycyrrhiza uralensis Fisch. and Glycyrrhiza glabra L (licorice) is a frequent adverse effect of Japanese traditional Kampo medicines, characterized by hypokalemia and hypertension due to the inhibition of 11 β -hydroxysteroid dehydrogenase type 2 (11 β -HSD2). While daily licorice dosage is a primary risk factor, it often fails to explain inter-individual variability, where some patients develop pseudohyperaldosteronism at low doses while others tolerate high doses. This updated narrative review redefines clinical risk factors based on recent pharmacokinetic discoveries, specifically the identification of 3- epi -18 β -glycyrrhetinic acid (3- epi -GA) and the role of intestinal microbiota. We reviewed recent pharmacological and pharmacokinetic evidence regarding the absorption, distribution, metabolism, and excretion of glycyrrhizin and its metabolites. We discuss the pharmaceutical factors altering the absorption of glycyrrhizin, one of the constituents of licorice, such as pH-dependent solubility in Schisandra -containing formulations and enzymatic competition by baicalin in Scutellaria -containing formulations. Importantly, we highlight the “epimerization phenotype,” where specific intestinal microbiota convert glycyrrhizin into 3- epi -GA. Unlike typical GA, 3- epi -GA is resistant to hepatic sulfation by sulfotransferase (SULT) 2A1, leading to prolonged accumulation. Furthermore, hypoalbuminemia increases free metabolite levels, potentially facilitating direct luminal access to renal tubules via glomerular filtration. Combined with the age-related decline in 11 β -HSD2 activity and renal excretion via organic anion transporters, these factors create a high-risk metabolic profile. We propose a precision medicine approach for risk assessment that integrates formulation characteristics, host intestinal microbiota function, and physiological reserve, moving beyond simple dosage counting to prevent this iatrogenic condition.
Related
- Giant Keratinocyte Carcinomas: Clinical, Histopathological, Molecular and Health-System Factors with Therapeutic Implications—A Structured Narrative Review
- Evaluating Acupuncture for Chemotherapy-Induced Peripheral Neuropathic Pain: A Narrative Review of Clinical Evidence and Mechanistic Perspectives
- Influencing Factors of Medical Narrative Competence Among Clinical Nurses in China: A Systematic Review and Meta‐Analysis
- Social Determinants of Health and Behavioral Risk Factors in the Tuberculosis-Type 2 Diabetes Syndemic: A Narrative Review
- De-escalating Therapy in Obstructive Sleep Apnoea After Glucagon-Like Peptide-1 Receptor Agonist-Induced Weight Loss: A Narrative Review
BibTeX
@article{yoshino2026clinical,
title = {{Clinical risk factors of licorice-induced pseudohyperaldosteronism: a 2026-updated narrative review}},
author = {Tetsuhiro Yoshino and Toshiaki Makino},
journal = {Frontiers in Pharmacology},
year = {2026},
month = may,
doi = {10.3389/fphar.2026.1840515},
url = {https://doi.org/10.3389/fphar.2026.1840515},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical risk factors of licorice-induced pseudohyperaldosteronism: a 2026-updated narrative review
AU - Tetsuhiro Yoshino
AU - Toshiaki Makino
PY - 2026
DA - 2026/05/28
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1840515
UR - https://doi.org/10.3389/fphar.2026.1840515
AB - Pseudohyperaldosteronism induced by the root of Glycyrrhiza uralensis Fisch. and Glycyrrhiza glabra L (licorice) is a frequent adverse effect of Japanese traditional Kampo medicines, characterized by hypokalemia and hypertension due to the inhibition of 11 β -hydroxysteroid dehydrogenase type 2 (11 β -HSD2). While daily licorice dosage is a primary risk factor, it often fails to explain inter-individual variability, where some patients develop pseudohyperaldosteronism at low doses while others tolerate high doses. This updated narrative review redefines clinical risk factors based on recent pharmacokinetic discoveries, specifically the identification of 3- epi -18 β -glycyrrhetinic acid (3- epi -GA) and the role of intestinal microbiota. We reviewed recent pharmacological and pharmacokinetic evidence regarding the absorption, distribution, metabolism, and excretion of glycyrrhizin and its metabolites. We discuss the pharmaceutical factors altering the absorption of glycyrrhizin, one of the constituents of licorice, such as pH-dependent solubility in Schisandra -containing formulations and enzymatic competition by baicalin in Scutellaria -containing formulations. Importantly, we highlight the “epimerization phenotype,” where specific intestinal microbiota convert glycyrrhizin into 3- epi -GA. Unlike typical GA, 3- epi -GA is resistant to hepatic sulfation by sulfotransferase (SULT) 2A1, leading to prolonged accumulation. Furthermore, hypoalbuminemia increases free metabolite levels, potentially facilitating direct luminal access to renal tubules via glomerular filtration. Combined with the age-related decline in 11 β -HSD2 activity and renal excretion via organic anion transporters, these factors create a high-risk metabolic profile. We propose a precision medicine approach for risk assessment that integrates formulation characteristics, host intestinal microbiota function, and physiological reserve, moving beyond simple dosage counting to prevent this iatrogenic condition.
SN - 1663-9812
ER -